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Mycobacterium ulcerans (MU) infection causes the disfiguring necrotic skin disease, Buruli ulcer (BU).
While vaccination with Mycobacterium bovis BCG provides nominal antigenic cross-reactivity for induc-
tion of immunity against experimental MU infection, a mycobacterial species with greater genetic homol-
ogy to Mycobacterium ulcerans may serve as a richer source of cross-protective immunogens and lack the
pathological features of MU-based vaccines. Mycobacterium marinum, a highly homologous genetic rela-
tive of MU, could be used to satisfy these criteria and, as such, we have generated a recombinant M. mar-
inum strain expressing the immunodominant, protective MU-Ag85A. The immunogenicity and protection
achieved by murine vaccination with this strain are superior to standard BCG vaccination and may serve
as a foundation for developing more effective BU vaccines.
 2016 The Authors. Published by Elsevier Ltd. This is anopenaccess article under the CCBY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Buruli ulcer (BU), one of 17 neglected tropical diseases (NTDs)
prioritized by the WHO, has become an emerging health problem
largely centered to Sub-Saharan Africa, Australia, and Japan [1–
3]. Over 50% of BU cases afflict children less than 15 years of age
[4]. Despite the progress made in early detection and treatment
of BU, surgical excision of the lesions combined with skin grafting
remains the only treatment for advanced ulcers. There are cur-
rently no specific prophylactic treatments for BU, and thus an effi-
cacious BU vaccine would be imperative to protect at-risk
populations in hyper-endemic areas.
Attempts to generate an efficacious vaccine for BU have met
with limited success, although Mycobacterium bovis bacille
Calmette-Guérin (BCG) vaccination transiently protected both
humans and mice in experimental models [5–9]. Additionally,
use of a DNA vaccine encoding the immunodominant Mycobac-
terium ulcerans mycolyl transferase, Ag85A (MU-Ag85A), imparted
temporary protection similar to BCG vaccination [10]. We have
recently shown that a subcutaneous recombinant BCG vaccine
which heterologously expresses the MU-Ag85A protein conferred
superior protection against murine Buruli ulcer compared to BCG
or Ag85A vaccination by significantly increasing length of survivalpost-challenge [11]. While vaccination with BCG provides nominal
antigenic cross-reactivity for induction of protective memory
against M. ulcerans infection, a mycobacterial species with greater
genetic homology to M. ulcerans may serve as a richer source of
cross-protective immunogens. Indeed, prior inoculation with the
attenuated mycolactone-deficient MU 5114 also confers short-
term protection against challenged mice [12]. However, despite a
reduction in virulence, this strain may still retain factors which
inhibit the development of fully effective immunological memory
[13].
We hypothesized that a more efficacious MU vaccine design
strategy would involve a mycobacterial strain which lacks both
the virulence and potential immunomodulatory properties associ-
ated with an MU-based vaccine, while still expressing high levels
of orthologous antigens. To satisfy these criteria, we chose the
close genetic relative, Mycobacterium marinum, which shares up
to 99.6% nucleotide identity with MU [14–17]. Despite this exten-
sive genetic homology, infection with M. marinum causes compar-
atively minor and typically indolent, granulomatous skin lesions.
In the present study, we hypothesized that vaccination with M.
marinum or recombinant strains expressing MU-Ag85A would pro-
vide immunogenic antigens but lack the immunosuppressive fac-
tors accompanying the more virulent MU background. A study by
Fenner et al. published in the late 1950’s supported the potential
use of M. marinum to induce protective immunity against Buruli
ulcer [18]. Mice that were inoculated intradermally in the foot
pad with Mycobacterium balnei (later renamed M. marinum) and
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compared to those primed intradermally with BCG [18]. We were
interested in expanding upon this work by examining the follow-
ing parameters not investigated in this previous study: (1) the
use of lower-dose, subcutaneously administered (a more physio-
logically relevant route) M. marinum and recombinant M. marinum
strains; (2) the effects of vaccination on lifespan of MU-challenged
mice; (3) the assessment of vaccine immunogenicity.
To this end, M. marinum (Aronson) was transformed with an
empty vector (pHA) or an overexpression construct encoding
MU-Ag85A, and large quality-controlled vaccine accession lots
were generated as previously described [19]. Briefly, quality con-
trol was performed on at least three random vials of each vaccine
accession lot by multiple methods. These included Western analy-
sis of heterologous antigen expression, quantification of colony
forming units, lack of contamination, and assessment of plasmid
stability by gel electrophoresis and sequencing of the recombinant
insert.
To determine if vaccination with M. marinum MU-Ag85A could
generate antigen-specific adaptive immune responses, C57BL/6
mice were primed with 107 bacilli by intravenous (IV) injection
to observe maximal immune responses. All animal studies were
approved by the Duke University IACUC. At intervals ranging from
1 to 8 weeks post-prime, MHCII tetramer staining of peripheral
lymphocytes was used to quantify the percentage of CD4+ T cells
which recognized Ag85A. In order to assess if a heterologous
mycobacterium could be used to boost initial T cell proliferation,
an intravenous dose of 107 Mycobacterium smegmatis expressing
MU-Ag85A was given at 8 weeks post-prime. As seen in Fig. 1A,
M. marinum MU-Ag85A induced significantly larger populations
of Ag85A-specific helper T cells compared to M. marinum pHA vac-
cinated or unprimed mice at several time points post-prime and
boost. Background tetramer-positive T cell populations during M.
marinum pHA priming were most likely due to endogenous expres-
sion of Ag85A. To determine if the antigen-specific T cells produced
during vaccination could generate Th1 responses, C57BL/6 mice
were vaccinated as in Fig. 1A. IFNc+ splenocytes were then quanti-Fig. 1. Expression of MU-Ag85A by M. marinum exhibits enhanced immunogenicity. A. C
using 107 M. marinum pHA (gray) orM. marinumMU-Ag85A (black) (n = 5 mice for each g
performed to quantify levels of CD4+ T cells bound to MHCII-Ag85 tetramer. At 8 we
expressing MU-Ag85A. Error bars represent standard deviation of the mean. Asterisks ind
marinum MU-Ag85A groups. ⁄p < 0.01, ⁄⁄p < 0.003 B. C57BL/6 mice were left unprimed (w
marinum MU-Ag85A (black) and boosted with 107 M. smegmatis expressing MU-Ag8
stimulation with MU-Ag85A peptide or heat killed M. ulcerans 1615 (HKMU). ELISPOT s
stimulation. Error bars represent standard deviation of the mean. Asterisks indicate stat
C57BL/6 mice were left unprimed (hashed black) or were subcutaneously (SC) primed
isolated and flow cytometric analysis was performed to quantify levels of CD4+ T cells
indicate statistical analysis by the Student’s t-test (n = 5 mice for each group) comparinfied by ELISPOT following in vitro stimulation with either MU-
Ag85A peptide (FQAAYNAAGGHNAVWNFDDN) or heat-killed M.
ulcerans 1615 (HKMU). Vaccination with M. marinum and M. mar-
inum MU-Ag85A both significantly increased the number of IFNc+
splenocytes compared to unprimed mice, suggesting that genetic
identity may heighten immune recognition of shared antigens
between MU and M. marinum (Fig. 1B). Interestingly, M. marinum
MU-Ag85A yielded even greater levels of IFNc+ splenocytes com-
pared to M. marinum pHA (p < 0.001). This suggests that antigen
expression in the M. marinum background amplified the respon-
siveness of functional Th1 cells expanded by vaccination to endoge-
nous levels of Ag85A expressed by M. ulcerans bacteria.
Importantly, subcutaneous priming with M. marinum MU-
Ag85A also yielded significantly greater antigen-specific T cell pop-
ulations compared toM. marinum alone, though this route induced
lower absolute percentages which peaked at a later time point
compared to the intravenous priming (Fig. 1C). However, upon
examination of the fold increase of antigen-specific CD4+ T cells
induced by M. marinum MU-Ag85A compared to M. marinum vac-
cination at the two strongest respective time points for each route,
subcutaneous priming yielded higher fold-increases for weeks 3
and 4 post-prime (2.1 and 2.5-fold, respectively) versus weeks 2
and 3 following IV priming (1.7 and 1.8-fold, respectively).
Protective efficacy of the M. marinum vaccine was examined in
the murine footpad challenge model. To recapitulate a more phys-
iologically relevant vaccination route as used in humans, mice
were subcutaneously primed with 107 M. marinum or M. marinum
MU-Ag85A and boosted with M. smegmatis MU-Ag85A. Mice were
then challenged with 105 virulent MU 1615 via an intradermal
footpad route two weeks post-boost. Footpad tissue sections were
stained with hematoxylin and eosin at 12 weeks post-challenge
(Fig. 2A). Strikingly, while extensive tissue swelling, loss of epider-
mal integrity, and necrosis were observed in unprimed mice, both
M. marinum andM. marinumMU-Ag85A vaccinated animals exhib-
ited less pathology. Additionally, diminished tissue edema was
observed within histological footpad sections from M. marinum
MU-Ag85A vaccinated mice compared to M. marinum vaccination.57BL/6 mice were left unprimed (hashed black) or were intravenously (IV) primed
roup). At various time points, PBMCs were isolated and flow cytometric analysis was
eks post-prime (black arrow), mice were intravenously boosted with 107 Msmeg
icate statistical analysis by the Student’s t-test comparing theM. marinum pHA toM.
hite) or were intravenously vaccinated using 107 M. marinum-pHA (hashed) or M.
5A 8 weeks later. Two weeks following the boost, splenocytes were isolated for
pot forming units (SFU) were used to quantify IFNc+ splenocytes following 24 h of
istical analysis using the Student’s t-test (n = 5 mice for each group). ⁄⁄p < 0.001 C.
using 107 M. marinum pHA (gray) or M. marinum MU-Ag85A (black). PBMCs were
bound to MHCII-Ag85 tetramer. Error bars represent standard deviation. Asterisks
g the M. marinum pHA to M. marinum MU-Ag85A groups. ⁄⁄p < 0.001.
Fig. 2. Decreased pathology and significant protection conferred by M. marinum during MU challenge. A. Displayed are representative H&E stained footpad tissue sections
from 12 week MU-infected mice which had been left unprimed (left) or subcutaneously primed withM. marinum (middle) or M. marinum MU-Ag85A (right) for eight weeks,
followed by a two week boost with M. smegmatis MU-Ag85A. Paws of unprimed mice consistently showed ulceration (loss of epidermis, arrow) with significant necrosis (⁄),
inflammatory infiltrate, and collections of bacteria (arrowheads). Some edema (E) was observed inM. marinum primed mice but was less common inM. marinumMU-Ag85A
primed mouse footpads. Scale bar, 100 lm. B. Mice were vaccinated as above (unprimed; white, M. marinum pHA; hashed, M. marinum MU-Ag85A; black) and challenged
with 105 MU1615. At 5 and 12 weeks post-challenge, mice were euthanized and smears of footpad homogenates were auramine-rhodamine stained. Acid-fast bacilli (AFB)
were quantified under 1000 magnification. Error bars represent standard deviation of the mean counts across images in each group. Asterisks indicate statistical analysis
using the Student’s t-test (n = 16 images per group: 4 mice per group, 4 images per footpad). ⁄⁄p < 0.002 C. Survival (time to euthanasia) was assessed in MU-challenged mice
which had been left unprimed (black) or subcutaneously primed with BCG pHA (green),M. marinum (red), orM. marinumMU-Ag85A (blue) for eight weeks, followed by a two
week boost withM. smegmatisMU-Ag85A. Asterisks indicate statistical analysis ofM. marinum andM. marinumMU-Ag85A versus BCG by the Mantel-Cox test (n = 10 for each
group). ⁄⁄p < 0.003.
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a correlation between the intensity of footpad swelling and bacte-
rial load in infected tissues [20]. To determine if the observed
reduction in tissue pathology associated withM. marinum vaccina-
tion correlated with lower bacterial burdens, challenged mice were
euthanized for isolation of persistent MU 1615 within footpads.
Acid-fast bacilli present in smears from filtered footpad homoge-
nates were stained with auramine-rhodamine [11,21] at 5 and
12 weeks post-challenge (Fig. 2B). At both time points, subcuta-
neous M. marinum vaccination significantly reduced the average
footpad bacterial burden compared to unprimed mice by 2.8-log
and 1.5-log, respectively. Similarly, M. marinum MU-Ag85A
reduced burdens by 3.0-log and 2.1-log compared to unprimed
mice at 5 and 12 weeks post-infection (p < 0.001). Interestingly,
expression of MU-Ag85A also conferred a significant 0.54-log
reduction in bacteria compared to M. marinum at week 12
(p < 0.002).
Finally, a long-term protection study was performed to deter-
mine survival of vaccinated mice post-challenge (Fig. 2C), whereby
protection conferred by vaccination was assessed by mean lifes-
pan. Once MU infection caused vertical footpad swelling to surpass
4.5 mm, mice were euthanized to end suffering. As previously
demonstrated, BCG vaccination temporarily increased the averagemouse lifespan from 7.1 weeks for unprimed mice to 12.6 weeks
[9]. Mice vaccinated with M. marinum and M. marinum MU-
Ag85A displayed significantly longer survival compared to BCG
vaccination, with mean survival reaching 24 weeks (p < 0.003)and
over 26 weeks (p < 0.002), respectively. Despite significant differ-
ences in immunogenicity and bacterial burden between M. mar-
inum and M. marinum MU-Ag85A vaccinated mice, no significant
increase in protection was observed upon expression of MU-
Ag85A. This result could potentially be due to the 98.5% amino acid
identity between MU-Ag85A and M. marinum Ag85A, whereby
expression of the M. marinum protein may not contribute a truly
novel and protective MU-specific antigen. The protection conferred
by subcutaneous injection of M. marinum does suggest that there
may be other immunodominant antigens endogenously expressed
by M. marinum which provide cross-protection against M. ulcerans
(Fig. 2B).
Due to the substantial reduction in quality of life for Buruli ulcer
patients, the generation of an effective prophylactic vaccine would
be greatly beneficial for endemic areas. Attenuated recombinantM.
marinum strains expressing potential immunodominant, protec-
tive MU specific antigens could represent alternative and improved
vaccine strategies for Buruli ulcer. Since M. marinum is known to
cause skin disease in humans, we examined several M. marinum
B.E. Hart et al. / Trials in Vaccinology 5 (2016) 88–91 91mutants, DkasB, Dmag24-1, and DRD1-6 (gift from Dr. Lalita
Ramakrishnan), for attenuation in vivo. All of these mutants exhib-
ited reduced virulence in mice compared to wildtype (data not
shown) and may represent safer vaccine candidates.
We have shown that M. marinum can be used to effectively
express recombinant M. ulcerans antigens and, when applied as a
vaccine, induce host antigen-specific T cell responses, heightened
recognition of M. ulcerans antigens, reduced pathological damage,
decreased bacterial burden, and increased survival after MU chal-
lenge. Continued work to uncover novel immunodominant anti-
gens for expression in attenuated M. marinum backgrounds could
further increase vaccine efficacy against Buruli ulcer.Acknowledgements
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